Sigilon nears first clinical test of cell shielding tech with $80M series B

With its $80.3 million series B round, Sigilon is planning to bring the first of its shielded cell therapies into the clinic, while also advancing toward INDs on four other programs.

Canada Pension

Read the full 326 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE